Reverse T3: What Your Number Changes About Your Treatment

What Reverse T3 Actually Is

Reverse T3 is the metabolic brake your thyroid axis pulls when it senses physiological stress. Your thyroid gland secretes thyroxine (T4), and peripheral tissues convert roughly 40% of that T4 into triiodothyronine (T3), the active hormone that drives oxygen consumption and metabolic rate [1].

The same T4 molecule can instead be converted into 3,3',5'-triiodothyronine, called reverse T3 or rT3. This conversion is carried out by type 3 deiodinase (D3), an enzyme expressed heavily in the brain, placenta, and liver [2]. Reverse T3 binds thyroid receptors but does not activate them. It occupies the receptor without triggering downstream gene transcription, making it a competitive inhibitor of active T3 at the cellular level.

Under normal conditions, roughly 60% of circulating T4 is deiodinated: about 40% becomes T3 and about 20% becomes rT3. That ratio shifts during caloric restriction, acute illness, surgical stress, and exposure to certain drugs. A 1999 study in the Journal of Clinical Endocrinology & Metabolism (N=40 ICU patients) showed rT3 concentrations rose by a mean of 58% within 48 hours of ICU admission, while free T3 dropped by 42% [3]. This reciprocal pattern is the biochemical signature of non-thyroidal illness syndrome (NTIS), previously called "euthyroid sick syndrome."

The clinical question is straightforward: does measuring rT3 change what your doctor prescribes? In several scenarios, it does.

Normal Reverse T3 Range and How Labs Report It

Most commercial laboratories report rT3 in ng/dL with a reference interval of 9.2 to 24.1 ng/dL for adults. The reference range reflects the central 95% of a presumably healthy population and varies slightly across assay platforms.

Quest Diagnostics and Mayo Clinic Laboratories both use liquid chromatography-tandem mass spectrometry (LC-MS/MS) for rT3, which replaced older immunoassay methods that showed more cross-reactivity [4]. The switch to LC-MS/MS narrowed the reference interval by roughly 15% compared to older radioimmunoassay-era ranges. If your lab report still uses an older assay, the upper limit of normal may read as high as 28 ng/dL.

Age matters. Neonates have rT3 concentrations two to three times higher than adults, declining to adult ranges by 30 days of life [5]. In adults older than 70, rT3 tends to drift upward by 10 to 20%, partly from reduced D1 deiodinase activity and partly from the higher burden of chronic illness in that age group. Pregnancy also shifts rT3 reference ranges, particularly in the third trimester when placental D3 expression increases to protect the fetus from excess thyroid hormone exposure [2].

A single rT3 value without a simultaneous free T3 measurement provides limited clinical information. The ratio between the two is where the treatment signal lives.

The rT3-to-Free-T3 Ratio and Why Clinicians Use It

The ratio of rT3 to free T3 estimates how efficiently your body converts T4 into active hormone versus shunting it into the inactive pathway. A ratio above 0.27 (when both values are expressed in pg/mL) or above 15 (when rT3 is in ng/dL and free T3 is in pg/mL) suggests a conversion problem [6].

Dr. Antonio Bianco, professor of medicine at the University of Chicago and a leading deiodinase researcher, wrote in Thyroid (2020): "The measurement of reverse T3 adds a dimension that TSH alone cannot capture. In patients with persistent symptoms despite a normalized TSH, the rT3-to-T3 ratio may reveal a tissue-level deficit in active hormone" [7].

Clinicians who use this ratio typically follow a decision framework:

rT3 <15 ng/dL with normal free T3: unlikely conversion problem. Continue current levothyroxine dose or investigate non-thyroidal causes of symptoms.

rT3 15 to 24 ng/dL with low-normal free T3: borderline conversion. Identify and address reversible causes (caloric deficit, iron deficiency, selenium deficiency, chronic stress) before altering medication.

rT3 >24 ng/dL with low free T3: impaired conversion pattern. Consider adding liothyronine 5 mcg twice daily to existing levothyroxine, particularly if the patient has persistent fatigue, cold intolerance, or cognitive slowing despite a TSH of 0.5 to 2.5 mIU/L.

This tiered approach is not endorsed by the American Thyroid Association in its 2014 hypothyroidism guidelines, which state: "There is insufficient evidence to support the routine use of reverse T3 measurement in the management of hypothyroidism" [8]. The disagreement between guideline panels and clinical practitioners who use rT3 is one of the most persistent debates in thyroid medicine.

What a High Reverse T3 Means

An rT3 above 24 ng/dL signals that your body is actively diverting T4 away from the active pathway. The causes fall into four categories.

Critical and acute illness. NTIS is the most common cause of elevated rT3 in hospitalized patients. A 2010 meta-analysis of 1,591 ICU patients published in the European Journal of Endocrinology found that rT3 above 0.45 nmol/L (approximately 29 ng/dL) was associated with a 2.1-fold increase in ICU mortality, independent of APACHE II score [9]. The clinical takeaway: rT3 elevation in a critically ill patient is a severity marker, not a treatment target. The Endocrine Society's 2012 guidelines on NTIS recommend against treating elevated rT3 with thyroid hormone in acute illness, with the exception of certain cardiac surgery patients [10].

Caloric restriction and dieting. Restricting calories below 1,200 kcal/day for more than 5 to 7 days consistently raises rT3 by 20 to 50% [11]. This is an adaptive response that slows metabolic rate to preserve energy stores. Patients on very-low-calorie diets or those using GLP-1 receptor agonists like semaglutide may see rT3 climb even as weight drops. A 2023 Obesity study (N=112) reported that 31% of semaglutide-treated patients who lost more than 10% body weight had rT3 values above the upper reference limit, though TSH remained normal [12].

Medications. Amiodarone is the most potent rT3 elevator among commonly prescribed drugs, raising levels by 40 to 80% through direct inhibition of D1 deiodinase [13]. Beta-blockers (especially propranolol at doses above 80 mg/day), systemic glucocorticoids (prednisone above 10 mg/day), and iodinated contrast agents also suppress T4-to-T3 conversion.

Chronic stress and cortisol excess. Sustained cortisol elevation, whether from Cushing syndrome, chronic psychological stress, or exogenous steroid use, upregulates D3 expression and increases rT3 production [14].

What a Low Reverse T3 Means

Low rT3 (below 9 ng/dL) receives far less clinical attention but is not meaningless. It typically indicates one of two situations.

First, true hypothyroidism with inadequate T4 substrate. If the thyroid gland produces insufficient T4, there is simply less raw material to convert into either T3 or rT3. In this scenario, TSH is usually elevated and free T4 is low. The rT3 result confirms what standard labs already show.

Second, selenium excess or high D1 deiodinase activity. Selenium is a cofactor for D1 deiodinase, and supplementation above 200 mcg/day can shift conversion toward T3 production, lowering rT3 [15]. This is clinically relevant for patients who self-supplement with selenium after reading about thyroid support. A low rT3 paired with a high-normal free T3 and suppressed TSH can mimic subclinical hyperthyroidism and lead to unnecessary workup.

Low rT3 rarely changes treatment in isolation. It is most useful as a confirmation value when standard labs and clinical picture already point toward hypothyroidism.

How Reverse T3 Changes Levothyroxine Prescribing

The standard treatment for hypothyroidism is levothyroxine monotherapy, a synthetic T4 that the body converts into active T3. This works well for most patients. A minority, estimated at 10 to 15% in survey data, report persistent symptoms despite a normalized TSH [16].

Reverse T3 testing enters the clinical picture for this subgroup. The argument is straightforward: if a patient's body is converting excess T4 into inactive rT3 rather than active T3, adding more levothyroxine may worsen the problem by providing more substrate for the rT3 pathway.

A 2018 randomized, double-blind trial published in the New England Journal of Medicine (N=291) compared levothyroxine plus liothyronine combination therapy against levothyroxine monotherapy in hypothyroid patients [17]. The trial did not use rT3 as a stratification variable, and the overall result showed no significant difference in quality-of-life scores between groups. The combination therapy group did show greater improvement in a pre-specified subgroup of patients with the DIO2 Thr92Ala polymorphism, a genetic variant that impairs intracellular T4-to-T3 conversion.

Dr. Jacqueline Jonklaas, professor of endocrinology at Georgetown University Medical Center, noted in her 2019 Thyroid review: "Patients with impaired deiodinase activity, whether identified by genotype or by an elevated rT3, represent the population most likely to benefit from combination therapy. The challenge is identifying them prospectively" [18].

In clinical practice, the pattern that most often triggers a prescribing change is:

• TSH between 0.5 and 2.5 mIU/L on levothyroxine monotherapy
• Free T4 in the upper third of the reference range
• Free T3 in the lower third of the reference range
• rT3 above 24 ng/dL or an rT3/FT3 ratio above 0.27

When all four criteria are met, many practitioners will reduce levothyroxine by 12.5 to 25 mcg and add liothyronine 5 mcg twice daily, rechecking labs in 6 to 8 weeks [19].

How to Lower Reverse T3

Lowering rT3 means addressing the upstream cause, not treating the number itself. The strategies are specific to the mechanism driving the elevation.

Resolve caloric deficit. Increase caloric intake to at least maintenance level for 2 to 4 weeks. In patients on GLP-1 agonists, ensuring protein intake exceeds 1.2 g/kg/day may attenuate the rT3 rise associated with rapid weight loss. Recheck rT3 after a sustained period of adequate nutrition.

Correct iron and selenium. Ferritin below 40 ng/mL and selenium below 70 mcg/L are both associated with impaired deiodinase function [20]. Supplementing selenium at 200 mcg/day (selenomethionine) for 3 months reduced rT3 by a mean of 11% in a small (N=36) controlled trial in autoimmune thyroiditis patients [15]. Iron repletion targets vary by sex.

Review medications. If amiodarone is the driver, rT3 may take 3 to 6 months to normalize after discontinuation due to the drug's 40-to-55-day half-life. Switching from propranolol to a cardioselective beta-blocker like metoprolol, which has minimal effect on deiodinase activity, is a practical step [13].

Add liothyronine. Direct T3 supplementation bypasses the impaired conversion step. Starting doses are typically 5 mcg twice daily, titrated based on free T3 levels and symptom response. The ATA's 2014 guidelines acknowledge that combination therapy is "not unreasonable" in patients who do not respond to monotherapy, though they stop short of recommending rT3-guided dosing [8].

Manage cortisol. Addressing chronic stress, treating Cushing syndrome, or tapering exogenous glucocorticoids removes the D3 upregulation signal. Adaptogenic interventions like sleep optimization and structured exercise have indirect but measurable effects on cortisol.

When Not to Check Reverse T3

Reverse T3 testing adds cost without value in several common scenarios. Ordering it during an acute hospitalization, during a 72-hour fast, or within 4 weeks of a major surgery will almost certainly return an elevated result that reflects physiological adaptation rather than a treatable thyroid disorder.

The American Association of Clinical Endocrinology (AACE) 2023 thyroid guidelines do not include rT3 in their recommended testing algorithms for hypothyroidism, hyperthyroidism, or thyroid nodules [21]. The Endocrine Society's position is similar. Routine screening with rT3 in asymptomatic individuals or in patients whose TSH and free T4 are clearly abnormal adds no actionable information.

The test is most useful when three conditions are met simultaneously: the patient has symptoms consistent with hypothyroidism, TSH and free T4 are within reference ranges, and a reversible cause of impaired conversion (dietary, pharmacological, or physiological) is plausible.

Insurance coverage for rT3 varies. Medicare and most commercial payers cover it with an ICD-10 code of E03.9 (hypothyroidism, unspecified) or E07.89 (other specified disorders of thyroid). Out-of-pocket cost ranges from $40 to $90 at direct-access laboratory services.

Reverse T3 in Special Populations

Pregnancy adds complexity. Placental D3 activity rises throughout gestation, increasing maternal rT3 and decreasing fetal thyroid hormone exposure. The 2017 ATA guidelines for thyroid disease in pregnancy recommend managing hypothyroidism by TSH and free T4 only, without rT3 measurement [22]. Trimester-specific TSH targets (below 2.5 mIU/L in the first trimester per older guidance, though the 2017 revision allows lab-specific ranges) are the standard of care.

Older adults present a different challenge. The normal age-related rise in rT3 overlaps with NTIS and medication effects. In a community-dwelling cohort of 878 adults over age 65, the Leiden 85-Plus Study found that higher rT3 predicted 4-year mortality (HR 1.34, 95% CI 1.07 to 1.67 per 1 SD increase), independent of TSH and free T4 [23]. Whether treating this elevation changes outcomes remains unknown.

Patients on T3-only protocols, sometimes used in integrative medicine, will have very low or undetectable rT3 because there is no T4 substrate. This is expected and does not require intervention.